We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biopharma

Biopharma

Stay up to date on the topics that matter to you

Blake Forman profile page

Senior Science Writer

at Technology Networks

Blake pens and edits breaking news, articles and features on a broad range of scientific topics with a focus on drug discovery and biopharma. Blake earned an honors degree in chemistry from the University of Surrey, which involved a placement year at the Medicines and Healthcare products Regulatory Agency (MHRA) laboratory, where he developed new pharmaceutical testing methods. Blake also holds an MSc in chemistry from the University of Southampton. His research project focused on the synthesis of novel fluorescent dyes often used as chemical/bio-sensors and as photosensitizers in photodynamic therapy. Blake held several editorial-based roles before joining Technology Networks in 2024.

Education

University of Surrey

University of Southampton

Areas of Expertise

Mass spectrometry

Pharmacovigilance

Science communication

Analytical chemistry

Got a Question for Blake Forman?

Get in touch using the contact form linked here and we'll get back to you shortly.

Published Content

Total: 121

A close up of a woman's eye, the target of a new stem cell therapy to treat blindness.

Industry Insight

A Stem Cell Therapy Resembling a Contact Lens Hopes To Cure Blindness

Stem cell therapy using iPSC technology on the surface of the eye could cure blindness by replacing damaged corneal cells – a new hope for vision restoration.

A gloved hand holding a petri dish of bacteria testing four different antibiotics.

ABC Transporters: The Achilles Heel of Bacteria?

Discover how ABC transporters could offer a targeted approach to tackle drug-resistant bacteria and combat antimicrobial resistance.

3D structure of a protein molecule, which must be carefully purified before use as a biotherapeutic.

Protein Purification Meets Automation: Driving Efficiency in Biopharma

Discover how automation is transforming protein purification, reducing costs and accelerating biopharma drug development.

A woman wearing a VR headset against a neon background.

Industry Insight

AI-Driven Virtual Reality Labs Are Transforming Research

Discover how VR labs with AI assistants are transforming global research, enabling immersive training, real-time data sharing and equitable access.

A pair of hands holding a drug pen containing GLP-1 drugs for treating obesity.

GLP-1 Weight Loss Drugs Reduce Asthma Symptoms

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes data from over 60,000 patients.

A researcher in PPE holding a white mouse used for animal testing in drug discovery and development.

Industry Insight

Are Plans To Phase Out Animal Testing Realistic?

Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and scalable alternatives.

A scientist working on a bioreactor before performing downstream processing of the biopharmaceutical product.

Purification Technologies Advancing Downstream Processing of Biopharmaceuticals

Explore cutting-edge technologies and workflows advancing downstream processing in biopharma, driving purification efficiency and innovation in new therapies.

Drug capsules floating on a dark background with text about European pharma and US uncertainty overlaid.

What Could Lower US Drug Prices Cost the Rest of the World?

What happens if the US ties drug prices to other nations? Discover how the most-favored-nation policy could shake the global pharmaceutical industry.

A researcher holding up a hologram of a molecule in a pill, representing AI-driven anti-infective discovery.

Industry Insight

Anti-Infective Development Boosted by AI and Automation

Anti-infective discovery is evolving with AI and robotics – learn how UK researchers aim to cut development time and improve success rates.

The outside of a US FDA building, which has just announced a hold on new clinical trials sending patient's cells abroad.

FDA To Block Clinical Trials That Send US Patients’ Cells to Foreign Labs

The FDA is reviewing clinical trials that send US patients' cells to foreign labs, citing concerns over genetic data security. Learn more about the new regulations.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter